Oftalʹmologiâ (Oct 2014)

The results of diagnostic and treatment of patients with diabetic retinopathy and age-related macular degeneration at a diabetes type 2.

  • I. V. Vorobyova,
  • L. G. Mikhaleva,
  • A. S. Kochergin

Journal volume & issue
Vol. 11, no. 3
pp. 20 – 27

Abstract

Read online

Purpose: Explore the changing clinical and functional and morphological changes of the retina against application of angiogenesis inhibitor in patients with diabetes type 2 with comorbidity fundus: diabetic retinopathy (DR) and agerelated macular degeneration (AMD).Patients and Methods. In the main study group included 22 patients (22 eyes) with type 2 diabetes with combined fundus pathology DR and AMD. All patients before and after intravitreal injection of an angiogenesis inhibitor ranibizumab (Lucentis, Novartis) was assessed visual acuity, macular thickness and macular morphology based on the results of OCT, the retinal sensitivity according to the data of microperimetry (MAIA). The control group study included 30 people (15 healthy and 15 with type 2 diabetes without DR).Results. When comparing the main group with the control group was revealed that visual acuity in the main group (0,27±0,05) was significantly lower than in the control group (0,8±0,01, p <0.05); retinal thickness was significantly higher in the control group, and the retinal sensitivity was significantly lower. On the background of intravitreal injection of ranibizumab all patients with DR and AMD had significantly increase in visual acuity on average by 37 % (from 0,27±0,05 before treatment to 0,37±0,05 after treatment), a significantly reduction of macular thickness in 9 out of 9 areas, including the fovea centralis, an average of 32.6 % and increase retinal sensitivity by 24 % (from 11,75±1,68 (dB) to 14,58±1,68 (dB), (p <0.05). The correlations were found between visual acuity and retinal thickness, as well as between visual acuity and retinal sensitivity of the macula, before treatment r = –0,26, p <0.01 and r = 0,7 p <0.01, respectively, after treatment with r = –0,14, p <0.01 and r = 0,64, p <0.01, respectively. Conclusions. Intravitreal injection of angiogenesis inhibitor ranibizumab to patients with comorbidity fundus DR and AMD on a background of type 2 diabetes pathogenesis is justified and leads to a significant improvement in clinical and functional and morphological parameters of the retina.

Keywords